Korean J Gastroenterol.  2000 Jul;36(1):29-38.

Comparison of the Different Products of Omeprazole based Triple Therapy for Helicobacter pylori-Positive Peptic Ulcer Disease

• Kim HS
• Lee DK
• Kim KH
• Jeong YS
• Kim JW
• Seo JI
• Baik SK
• Kwon SO
• Cho MY

Abstract

BACKGROUND/AIMS
We prospectively compared the efficacy and safety of the two products of omeprazole based triple therapy in patients with Helicobacter pylori (H. pylori)-positive active peptic ulcer. METHODS: Seventy-four patients with endoscopically proven active peptic ulcer were divided into two groups: OAC-I group (n=37) which received the 6-weeks treatment of A product of omeprazole (20 mg, b.i.d.) plus 2 weeks treatment of amoxicillin (500 mg, b.i.d.) and clarithromycin (500 mg, b.i.d.); OAC-II group (n=37) which received 6 weeks treatment of B product of omeprazole (20 mg, b.i.d.) plus 2 weeks treatment of the same antibiotics. The H. pylori and ulcer healing status were assessed at baseline and at the end of the 6-week therapy. Gastrointestnal symptoms, adverse events were checked and the standard laboratory examination was performed at each visit. RESULTS: Eradication of H. pylori [intention to treat (n=77)/per protocol (n=66)] and healing rate of ulcer were 83.8%/ 96.9% and 93.8% in OAC-I group, 91.9%/100% and 97.1% in OAC-II group (P=0.477, P=0.608). No significant differences were found in symptom resolution, adverse events, and laboratory monitoring between the two groups. CONCLUSIONS: The two different products of omeprazole based triple therapy for ulcer showed similar healing rates and safety after 6-weeks treatment in patients with H. pylori-positive active peptic ulcer.

Keyword

Products of omeprazole; Peptic ulcer disease; Helicobacter pylori; ELISA; GenediaTM

MeSH Terms

Amoxicillin
Anti-Bacterial Agents
Clarithromycin
Enzyme-Linked Immunosorbent Assay
Helicobacter pylori
Helicobacter*
Humans
Omeprazole*
Peptic Ulcer*
Prospective Studies
Ulcer
Amoxicillin
Anti-Bacterial Agents
Clarithromycin
Omeprazole